Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea and a tenant company of JLABS@ TMC in Houston, Texas, announced that the Investigational New Drug application for BBT-877, a potent best-in-class drug candidate for Idiopathic Pulmonary Fibrosis, has been cleared by the US Food and Drug Administrati
The FDA has approved Celltrion and Tevas biosimilar of Roches breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US. All three are threatened by biosimilar competition, although Mylan and Celltrion will be unable to launch Herceptin in the US until the patent expires. Celltrion and Teva began an exclusive
Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform Collaboration leverages Ares Genetics antibiotic resistance database ARESdb Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens Vienna, Austria, Holzgerlingen, Germany and Amsterdam, The...
Rob Portman, R- Ohio, issued the following news release:. After a year-long investigation, Senator Portman, the chair of the Senate Permanent Subcommittee on Investigations, issued a report on November 18 into why kaleo increased the price of its naloxone drug EVZIO from $575 to $4,100 in just two-and-a-half years- all despite recommendations from
Under the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1. "This agreement with Innovare follows an already successful and long-lasting collaboration on this peptide", said Dr. "Using DelSiTech's platform, we have developed
Sarasota, FL 12/18/2018 Zion Market Research has published a new report titled "Personalized Medicine Market by Therapeutic Area, by Application, by End-User, and by Technology: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 2024". According to the report, the global personalized medicine market was valued at appro
"Global Stem Cell Therapy Industry" New Study On 2018-2025 Stem Cell Therapy Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast Added to Wise Guy Reports Database. New Study On "2018-2025 Stem Cell Therapy Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast" Added to Wise Guy Reports Databa
"\"\ "Herbal Extracts Market Worldwide Research Report\" " Herbal Extracts Market Worldwide Research Report by Ingredient, Application and Region Forecast till 2023. Pharmaceutical industry, especially herbal dietary supplements, is gaining acceptance in developed economies, which, in turn, would accelerate the sales of herbal extract during the fo
Under the Mallinckrodt name, its specialty generics business will be spun-off to shareholders and listed on the New York Stock Exchange. The inclusion of the Amitiza product in the non-promoted assets to be spun off brings added manufacturing facilities and employees in Japan, and diversified revenues further, according to Mallinckrodt.
Diabetic Foot Ulcer Pipeline Analysis report gives comprehensive insights on the various drugs being developed for the treatment of DFU. The report covers all the drugs that are in various phases of development. The pipeline focuses on novel pharmacologic drugs and regenerative medicines covering, antibodies, stem cell therapies, recombinant protei
Hauppauge, NY Serving as one of America's largest and oldest manufacturers of top-quality nutritional supplements for almost 50 years, Nature's Answer's family-owned and operated brand takes home the Best of Supplements award from Better Nutrition magazine featuring Brocco-Glutathione in the anti-aging category. In addition to using Setria ...
Agency: " Food and Drug Administration, HHS." FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, email@example.com. These public documents may be seen in the office of the Dockets Management Staff, Food and Drug Administration
Dec. 18 MORGANTOWN The Public Employees Insurance Agency Finance Board came to Morgantown Monday evening for a public hearing. "We expect you to have a moral and ethical stance of some nature that recognizes the value of the human beings in West Virginia.... We are the people of West Virginia.
Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston, MA, USA.. The development and manufacturing site will be leveraged as a CDMO by Rentschler...
Sophiris Bio Inc., a biopharmaceutical company studying topsalysin, a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today provides an update from its Phase 2 b study of topsalysin for localized prostate cancer, including top-line safety and biopsy results from the patient
Office Address: Department of Health and Human Services; Food and Drug Administration; Office of Acquisitions and Grants Services- Rockville; 4041 Powder Mill Road Beltsville MD 20705. Office of Acquisitions and Grants Services- Rockville. Pre-Solicitation Notice of Sole Source Intent: The Food and Drug Administration intends to award a five- year
Spending on medicines and healthcare in Australia witnessed steady growth in 2017, reflecting strong potential for new medicine development, infrastructure building and new entry/expansion opportunities. This report focuses its attention on pharmaceutical market in Australia and presents market trends, drivers and challenges facing the R&D...
Gainers Diffusion Pharmaceuticals Inc. shares rose 65.1 percent to $4.7225 after the US Patent Office awarded the company exclusive rights for the use of its TSC drug in conjunction with tPA for stroke treatment. Synergy Pharmaceuticals Inc. climbed 34.2 percent to $0.1073 after Health Canada accepted Cipher Pharmaceuticals' new drug submission for
Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that it has appointed Salma Jutt as Chief Commercial Officer. If EDSIVO? is approved by the FDA for the treatment of vascular Ehler
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and po
Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology, today provided updated data from three clinical trials for ATI-502, an investigational topical Janus
Nevada Attorney General Adam Paul Laxalt issued the following news release:. On January 5, 2015, Adam Paul Laxalt was sworn in as Nevada's 33rd attorney general, at the time making him the youngest attorney general in the nation. *initiated a working group to reduce Nevada's decades-in-the-making sexual assault kit backlog of nearly 8,000 untested
BOTHELL- Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder's Board of Directors granted a non-qualified stock option to purchase an aggregate of 270,000 shares of Alder's common stock to Carlos E. Campo
The U.A.E. becomes the first country in the Middle East to obtain pricing approval. ATLANTA, GA/ ACCESSWIRE/ December 17, 2018/ Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had been received for ILUVIEN from the United Arab Emirates Minist
DUBLIN and CAMBRIDGE, Mass., Dec. 17, 2018/ PRNewswire/ Alkermes plc and Biogen Inc. today announced that Alkermes has submitted a New Drug Application to the U.S. Food and Drug Administration for diroximel fumarate, a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis. Alkermes is seeking approval of di